Kestrel Therapeutics

Kestrel Therapeutics, founded in 2020 by Frank Haluska, is a clinical-stage biotechnology company focused on developing therapies for intractable cancers by targeting the most frequently mutated oncogenic drivers. The company's lead program is centered on creating potent, small-molecule inhibitors of pan-oncogenic-RAS, which are designed to be active regardless of the specific RAS isoform, mutation, or tumor histology. This approach aims to address a broad spectrum of RAS-driven cancers, which account for over 30% of all human cancers and have historically been difficult to treat.

The company's scientific strategy is based on a deep physical understanding of drug-target interactions to create precise and lethal treatments against cancer cells. Recent patents filed by Kestrel describe new GTPase KRAS mutant inhibitors that have shown activity in suppressing cancer cell proliferation and inhibiting key signaling pathways in preclinical studies. Based at the Pagliuca Harvard Life Lab in Allston, MA, Kestrel Therapeutics is part of a vibrant biotech ecosystem and leverages a data-driven approach in its research and development.

Founder, President, and CEO Frank Haluska, MD, PhD, brings extensive experience from previous leadership roles at Anchiano Therapeutics and ARIAD Pharmaceuticals, as well as academic positions at Harvard Medical School and Massachusetts General Hospital. His background includes a BA from Harvard University and dual M.D. and Ph.D. degrees from the University of Pennsylvania. The company is backed by prominent investors including Pfizer Ventures, Cormorant Asset Management, Santé Ventures, and S32, having raised capital through several funding rounds to advance its pipeline.

Keywords: oncology, RAS inhibitors, cancer therapy, drug discovery, biotechnology, KRAS mutation, targeted therapy, oncogenic drivers, small molecules, clinical-stage, cancer research, preclinical studies, GTPase KRAS, pan-RAS, molecular oncology, precision medicine, biopharmaceuticals, venture capital, intractable cancers, tumor histology